BamSEC and AlphaSense Join Forces
Learn More

Kiora Pharmaceuticals Inc.

NASDAQ: KPRX    
Share price (1/3/25): $3.63    
Market cap (1/3/25): $10.9 million
Search in Documents
Key Exhibits
External Links

Articles of Incorporation Filter

EX-3.1
from 8-K 1 page Certificate of Amendment to the Restated Certificate of Incorporation Pursuant to Section 242 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 1 page Certificate of Amendment to the Restated Certificate of Incorporation Pursuant to Section 242 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 17 pages Kiora Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law 1 Terms of Preferred Stock
12/34/56
EX-3.13
from S-1/A 18 pages Kiora Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56
EX-3.1
from 8-K 1 page Certificate of Amendment to the Restated Certificate of Incorporation Pursuant to Section 242 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 17 pages Third Amended and Restated Bylaws of Kiora Pharmaceuticals, Inc. Effective: August 1, 2022
12/34/56
EX-3.1
from 8-K 17 pages Kiora Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56
EX-3.11
from S-1/A 18 pages Kiora Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56
EX-3.11
from S-1/A 18 pages Terms of Preferred Stock
12/34/56
EX-3.2
from 8-K 17 pages Second Amended and Restated Bylaws of Kiora Pharmaceuticals, Inc., Effective: November 8, 2021
12/34/56
EX-3.1
from 8-K 3 pages Certificate of Ownership and Merger Merging Kiora Pharmaceuticals, Inc. With and Into Eyegate Pharmaceuticals, Inc. November 5, 2021
12/34/56
EX-3.1
from 8-K 10 pages Eyegate Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56
EX-3.1
from 8-K 1 page Certificate of Amendment to the Restated Certificate of Incorporation Pursuant to Section 242 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 1 page Certificate of Amendment to the Restated Certificate of Incorporation Pursuant to Section 242 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 2 pages Certificate of Amendment to the Restated Certificate of Incorporation Pursuant to Section 242 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 16 pages Eyegate Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56
EX-3.1
from 8-K 16 pages Eyegate Pharmaceuticals, Inc. Form of Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56
EX-3.5
from S-1/A 16 pages Eyegate Pharmaceuticals, Inc. Form of Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56
EX-3.1
from 8-K 12 pages Terms of Preferred Stock
12/34/56
EX-3.1
from 8-K 14 pages Eyegate Pharmaceuticals, Inc. Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56